N4 Pharma shares (LON:N4P) rallied on Wednesday after the firm updated investors on its research findings.

The pharmaceutical company said that it had conducted further research regarding its Nuvec delivery system.

Adding to previous findings, the company said that upon further analysis of its pDNA OVA results, this revealed demonstrated the immune response observed was “sufficient to have produced strong levels of antibodies specific for OVA.”

Last month, N4 Pharma confirmed that findings from its Nuvec product research had revealed a ‘clear adjuvent effect’ to deliver an immune response to mRNA and pDNA OVA antigens.

Nigel Theobald, CEO of N4 Pharma commented:

“These results are once again another positive step forward for our Nuvec(R) delivery platform. The data now shows Nuvec(R) is capable of producing specific and relevant strong levels of antibodies required for the development of vaccines and cancer treatments.

“We will continue to provide updates as we add to our already encouraging data package to aid our commercial collaboaration discussions. The production of a robust data package using the test antigen Ovalbumin provides compelling evidence of the potential for Nuvec(R) to be an effective delivery system for a potential partner’s specific DNA or RNA antigen. ”

N4 Pharma is a specialist pharmaceutical firm that develops delivery systems for vaccines and cancer treatment.

Shares in the company are currently +28.95% as of 10:23AM (GMT).